SUPPLEMENTARY INFORMATION: Section 4(d) of TSCA requires EPA to publish a notice in the **Federal Register** reporting the receipt of test data submitted pursuant to test rules promulgated under section 4(a) within 15 days after it is received.

I. Test Data Submissions

Test data for ortho-cresol was submitted by the Chemical Manufacturers Association Cresol Program Panel pursuant to a test rule a 40 CFR 799.1250. It was received by EPA on September 6, 1988. The submission describes a mutagenicity test on ortho-cresol in the *in vitro* transformation of BALB/C–3T3 cells assay in the presence of a rat liver cell activation system. Mutagenicity testing is required by this test rule.

Cresols are used as wire enamel solvents, automotive cleaners, and organic intermediates in manufacturing phenolic resins and phosphate esters. Additional uses of either individual isomers or mixtures are: In the production of several herbicides and disinfectants; as cleaning compounds, degreasers and antioxidants, and in ore flotation.

Test data for hexafluoropropene was submitted by E.I. Du Pont de Nemours and Company, Inc., pursuant to a test rule at 40 CFR 799.1700. It was received by EPA on September 2, 1988. The submission is an addendum to the final report, mutagenicity evaluation of hexafluoropropene in the CHO/HPRT assay, submitted to EPA on May 16, 1988. Mutagenicity testing is required by this test rule.

Fluoroalkenes are used as precursors in the manufacture of highly specialized polymers and elastomers.

EPA has initiated its review and evaluation process for these data submissions. At this time, the Agency is unable to provide any determination as to their completeness.

II. Public Record

EPA has established a public record for this TSCA section 4(d) receipt of data notice (docket number OPTS–44516). This record includes copies of all studies reported in this notice. The record is available for inspection from 8 a.m. to 4 p.m., Monday through Friday, except legal holidays, in the TSCA Public Docket Office, Rm. NE–G004, 401 M St., SW., Washington, DC 20460.

Authority: 15 U.S.C. 2603.

Dated: September 20, 1988.

Frank D. Kover,

Acting Director, Existing Chemical Assessment Division, Office of Toxic Substances.

[FR Doc. 88–22036 Filed 9–26–88; 8:45 am]

BILLING CODE 6560–50–M

GENERAL SERVICES ADMINISTRATION

Federal Acquisition Regulation (FAR): Agency Information Collection Activities Under OMB Review

AGENCY: Office of Acquisition Policy and Regulations (VP), GSA.

The GSA hereby gives notice under the Paperwork Reduction Act of 1980 that it is requesting the Office of Management and Budget (OMB) to renew expiring information collection 3090–0227, Termination Liability Schedule General Services Administration Acquistion Regulation Part 549. This regulation enables GSA to obtain communication servies in accordance with the specified terms and conditions of the applicable tariffs, which normally include Termination Liability (TL) provisions, and through the competitive acquisition process, which, also, normally includes TL provisions.

ADDRESSES: Send comments to Bruce McConnell, GSA Desk Officer, Room 3235, NEOB, Washington, DC, 20503, and to Mary L. Cunningham, GSA Clearance Officer, General Services Administration (CAIR), F Street at 18th, NW., Washington, DC 20405.

Annual Reporting Burden: Firms responding, 60; responses, 1 per year; average hours per response, 2.5; burden hours, 150.

FOR FURTHER INFORMATION CONTACT: Ida Ustad, 202/566–1224.

Copy of Proposal: A copy of the proposal may be obtained from the Information Collection Management Branch (CAIR), Room 3014, GS Bldg., Washington, DC 20405, or by telephoning 202–535–7691.

Dated: September 20, 1988.

Mary Cunningham,

Acting Director, Information Management Division (CAI).

[FR Doc. 88–22046 Filed 9–26–88; 8:45 am]

BILLING CODE 6820–61–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control

[Announcement No. 824]

National Institute for Occupational Safety and Health; Cooperative Agreement To Implement Asbestos Controls During Brake Shoe Replacement; Availability of Funds for Fiscal Year 1988

Introduction

The Centers for Disease Control (CDC), National Institute for Occupational Safety and Health (NIOSH), announces the availability of funds for Fiscal Year 1988 for a cooperative agreement to support the Ohio Technology Transfer Organization (OTTO) in the development of innovative approaches for disseminating information about the control of occupational safety and health hazards to small businesses. No other applications are solicited or will be accepted.

Authority

This program is authorized under section 22(e)(7) of the Occupational Safety and Health Act of 1970 and section 301(a) of the Public Health Service Act. The Catalog of Federal Domestic Assistance number is 13.283.

Purpose

The objectives of this program are:

1. To develop a demonstration program for dissemination of control technology to small businesses, by using State sponsored business assistance programs;
2. To increase the acceptance and awareness of specific health and safety controls;
3. To develop a generic model for disseminating control technology to small businesses.

Availability of Funds

It is expected that the cooperative agreement will be for a 3-year project period beginning on or about September 30, 1988. The estimated cost of this project is $35,000 for the first year and approximately $30,000 for each of the remaining 2 years. The second year and the subsequent year are subject to the availability of funds and satisfactory progress of the applicant in meeting the objectives of the cooperative agreement.

Single Source Justification

The project will develop useful information for small businesses based upon NIOSH control technology

research and will explore the utility of using small business assistance programs to disseminate this information about occupational safety and health controls. Small business assistance programs exist in most State governments but are unused for communicating occupational safety and health messages. Through this project a model will be developed that can be used by NIOSH to encourage the implementation of control technology in other States and industries by developing the appropriate materials and cost effective strategies to reach those at risk from the asbestos dust.

The State of Ohio has specialized resources that uniquely qualify it to develop a model dissemination program for brake shoe controls. It has linked these resources through the State's Transportation Research Center and the Ohio Technology Transfer Organization (OTTO). OTTO has agents located throughout the State's urban and rural areas so that the differences in gaining acceptance to controls between urban and rural settings can be addressed in the model. OTTO is characterized by an active network whose agents interact continuously with each other and commonly use the resources of the State's university system to find solutions to technical problems facing small business. Therefore, the Transportation Research Center, directed by the Ohio State University, is the natural connection for technical assistance in developing this model program.

The Transportation Research Center has facilities for testing braking systems that are unique in the United States. The staff of the Center has unrivaled expertise in the engineering performance of braking systems. This expertise, combined with the outreach and communications abilities of the OTTO agents and the technical evaluation of the controls completed by NIOSH staff, creates a unique situation with high probability of success. The Transportation Research Center as part of the Engineering Experiment Station at the Ohio State University will provide the technical support for developing materials to train those at risk to control exposure to asbestos dust during brake shoe replacement. These materials will be based upon the information developed by NIOSH about brake shoe controls. Without the unique capabilities of the Transportation Research Center, the development of the model could not be attempted.

The network linkage between OTTO and the Transportation Research Center already exists. Ohio State University (OSU), through its OSU/OTTO office, provides the principal technical support for OTTO. The Director of OSU/OTTO is also affiliated with the Engineering Experiment Station. OTTO is a nationally recognized leader in technology transfer to small businesses. It is geographically diverse with 34 agents located in the various public universities and community technical colleges throughout Ohio. Twenty community colleges and universities affiliated with OTTO have automative technology or automotive engineering programs. Because of its agent's physical location at the Ohio technical community colleges, OTTO representatives have close ties to the community. The ability of the agents to gain access to small businesses and to gain acceptance of the engineering control is necessary for the performing organization.

OTTO has a well motivated and experienced staff interested in developing this communication model. There is no other State that has the combination of facilities, expertise, and experience in providing new technologies to small businesses along with the geographic diversity inherent in the community college base agent network. The 10 years of OTTO's existence has stimulated similar programs in other States. However, these emerging programs have not yet developed the networks necessary for proficiency in technology transfer, nor do they have the necessary technical support to develop a model demonstration program to disseminate control technology to small businesses. The State of Ohio is attractive because it provides a wide variety of small business settings ranging from the highly industrialized to the rural. OTTO is experienced in dealing with small businesses in all these settings.

Cooperative Activities

A. Recipient (OTTO) Activities

1. Development of a strategy for disseminating occupational safety and health controls to small businesses.

2. identification of the appropriate information about the chosen engineering controls to be disseminated.

3. Development of a protocol that describes the process used to disseminate occupational safety and health control information to the target population including a timetable for the development and implementation of the project.

4. Submission of the proposed protocol and timetable to NIOSH for review. The recipient will implement the proposed dissemination strategy.

5. Development of program descriptions, guidelines, and documentation of procedures and techniques that can be used by others to disseminate occupational safety and health controls to small businesses.

6. Collaboration in the evaluation of all activities undertaken pursuant to the development and implementation of the proposed dissemination program. This evaluation will focus on the efficacy of the identification of the groups who can best reach the target audience and the acceptance of the controls proposed by the target audience.

B. CDC Activities

1. Collaborate in assessing the completeness of the definition of the audience to which the control information is directed.

2. Collaborate in assessing the adequacy and extent of the networks identified to disseminate the occuptational safety and health information.

3. Assess the methodology for disseminating the control information. Both NIOSH and the recipient will work together in exploring and developing new dissemination methods and determining their feasibility.

4. Provide the necessary information and support about recommended engineering control practices and procedures, and disposal methods associated with introducing asbestos controls for the brake shoe replacement or other targeted industries.

5. Collaborate as necessary in the interim or final evaluation of the proposed dissemination activities.

6. Collaborate in the exchange of information related to other potential occupational safety and health problems identified in the small businesses visited.

Review and Evaluation Criteria

The application will be reviewed in accordance with PHS Grants Administration Manual, Part 134, Objective Review of Grant Applications. An ad hoc committee will be convened to determine the merit of the application. The application will be reviewed and evaluated based on the following:

A. Understanding of the problem and the purpose of this cooperative agreement.

B. Ability to provide the staff, knowledge, and other resources to perform the responsibilities in this project, and the approach to be used in carrying out those responsibilities.

C. Steps to be taken in planning this project.

D. Schedule for accomplishing the initial planning and organizational phase of this project.

E. Qualifications and time allocations of the professional staff to be assigned to this project and the facilities, space, and equipment available for this project.

F. How the project will be administered, and the qualifications of the individual who will be responsible for its day-to-day administration.

Grantee Financial Participation

There are no grantee cost participation requirements for this program.

Other Review Requirements

Applications are not subject to review as governed by Executive Order 12372, Intergovernmental Review of Federal Programs.

Application Submission and Deadline

The originial and two unbound copies of the application (PHS 5161–1, revised 3/86) must be received on or before September 29, 1988 to Henry S. Cassell, III, Grants Management Officer, Grants Management Branch, PGO, Centers for Disease Control, 255 E. Paces Ferry Rd., NE., Room 300, MS E14, Atlanta, Georgia 30305, Telephone (404) 842–6575.

Where To Obtain Additional Information

Information may be obtained from: Nealean K. Austin, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control, 255 E. Paces Ferry Rd., NE., Room 300, MS E–14, Atlanta, Georgia 30305, Telephone (404) 842–6575.

Technical assistance may be obtained from: Theodore F. Schoenborn, Division of Physical Sciences and Engineering (DPSE), National Institute of Occupational Safety and Health, 4676 Columbia Parkway, Cincinnati, Ohio 43226, Telephone (513) 841–4305.

Dated: September 21, 1988.

Larry W. Sparks,

Acting Director National Institute for Occupational Safety and Health.

[FR Doc. 88–22019 Filed 9–26–88; 8:45 am]

BILLING CODE 4160–18–M

National Institute for Occupational Safety and Health; Meeting

The following meeting will be convened by the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control (CDC):

Name: Peer Review of NIOSH Low Back Injury Assessment Protocol

Date: October 4, 1988

Place: Division of Safety Research, Room 138B, 944 Chestnut Ridge Road, Morgantown, West Virginia 26505–2888

Time: 9:00 a.m.–3:30 p.m.

Status: Open to the public, limited only by space available.

Purpose: To conduct a peer review of a research protocol for a study to evaluate the validity of the NIOSH Low Back Atlas (LBA) of Standardized Tests/Measures.

Additional information may be obtained from: Roger M. Nelson, Ph.D., Division of Safety Research, NIOSH, Mail Stop S109, 944 Chestnut Ridge Road, Morgantown, West Virginia 26505–2888, Telephone: Commercial: (304) 291–4810, FTS: 923–4810.

Dated: September 22, 1988.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control.

[FR Doc. 88–22179 Filed 9–26–88; 8:45 am]

BILLING CODE 4160–19–M

Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee; Renewal

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration announces the renewal of the Cardiovascular and Renal Drugs Advisory Committee by the Secretary of Health and Human Services. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)).

DATE: Authority for this committee will expire on August 27, 1990, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA–30), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

Dated: September 19, 1988.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 88–21995 Filed 9–26–88; 8:45 am]

BILLING CODE 4160–01–M

Endocrinologic and Metabolic Drugs Advisory Committee; Renewal

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration announces the renewal of the Endocrinologic and Metabolic Drugs Advisory Committee by the Secretary of Health and Human Services. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463, 86 Stat. 770–776 (5 U.S.C. App. I)).

DATE: Authority for this committee will expire on August 27, 1990, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

Dated: September 19, 1988.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 88–21996 Filed 9–26–88; 8:45 am]

BILLING CODE 4160–01–M

Oncologic Drugs Advisory Committee; Renewal

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration announces the renewal of the Oncologic Drugs Advisory Committee by the Secretary of Health and Human Services. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–463), 86 Stat. 770–776 (5 U.S.C. App. I)).

DATE: Authority for this committee will expire on September 1, 1990, unless the Secretary formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Richard L. Schmidt, Committee Management Office (HFA–306), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–2765.

Dated: September 19, 1988.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 88–21997 Filed 9–26–88; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 88F–0310]

Hoechst-Celanese, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing

that Hoechst-Celanese, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of glyceryl esters of oxidatively refined montan wax acids as lubricants in the production of food-contact articles prepared for polyvinyl chloride and/or vinyl chloride copolymers.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C Street SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 8B4108) has been filed by Hoechst-Celanese, Inc., c/o 1150 17th St. NW., Washington, DC 20036, proposing that § 178.3770 *Polyhydric alcohol diesters of oxidatively refined (Gersthoffen process) montan wax acids* (21 CFR 178.3770) of the food additive regulations be amended to provide for the safe use of glyceryl esters of oxidatively refined (Gersthoffen process) montan wax acids as lubricants in the production of food-contact articles prepared from polyvinyl chloride and/or vinyl chloride copolymers.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: September 16, 1988.

Richard J. Ronk,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 88-22022 Filed 9-26-88; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 88N-0331]

Drug Export; M.V.C. 9+3® Multivitamin Concentrate

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that LyphoMed, Inc., has filed an application requesting approval for the export of the human drug M.V.C. 9+3® Multivitamin Concentrate to Canada.

ADDRESS: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Rudolf Apodaca, Division of Drug Labeling Compliance (HFD-310), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8063.

SUPPLEMENTARY INFORMATION: The Drug Export Amendments Act of 1986 (Pub. L. 660) (section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)) provides that FDA may approve applications for the export of drugs that are not currently approved in the United States. The approval process is governed by section 802(b) of the act. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that LyphoMed, Inc., 2020 Ruby St., Melrose Park Il 60160, has filed an application requesting approval for the export of the human drug M.V.C. 9+3® Multivitamin Concentrate, to Canada. This formulation is indicated as daily multivitamin maintenance dosage for adults and children aged 11 and above receiving parenteral nutrition. The application was received and filed in the Center for Drug Evaluation and Research on September 12, 1988, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by October 7, 1988, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802, Pub. L. 99-660 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and Research (21 CFR 5.44).

Dated: September 20, 1988.

Daniel L. Michels,

Director, Office of Compliance, Center for Drug Evaluation and Research.

[FR Doc. 88-22021 Filed 9-26-88; 8:45 am]

BILLING CODE 4160-01-M

Consumer Participation; Notice of Open Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the following district consumer exchange meeting: MINNEAPOLIS DISTRICT OFFICE, chaired by John Feldman, District Director. The topics to be discussed are vitamin and mineral supplements and fat and cholesterol labeling.

DATE: Wednesday, October 5, 1988, 1 p.m. to 3 p.m.

ADDRESS: Whitney Senior Center, 1125 Northway Dr., St. Cloud, MN 56301.

FOR FURTHER INFORMATION CONTACT: Donald W. Aird, Jr., Consumer Affairs Officer, Food and Drug Administration, 240 Hennepin Ave., Minneapolis, MN 55401, 612-334-4100.

SUPPLEMENTARY INFORMATION: The purpose of this meeting is to encourage dialogue between consumers and FDA officials, to identify and set priorities for current and future health concerns, to enhance relationships between local consumers and FDA's District Offices, and to contribute to the agency's policymaking decisions on vital issues.

Dated: September 21, 1988.

John M. Taylor,

Associate Commissioner for Regulatory Affairs.

[FR Doc. 88-21994 Filed 9-26-88; 8:45 am]

BILLING CODE 4160-01-M

Public Health Service

Advisory Committees; Meetings; October

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), announcement is made